Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nanobiotix Presents Successful Phase I Results for NBTXR3 at ASCO

Published: Tuesday, June 03, 2014
Last Updated: Tuesday, June 03, 2014
Bookmark and Share
Final results demonstrate a very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas.

NANOBIOTIX has announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.

The Phase I clinical study established that intratumoral injection of NBTXR3 followed by radiotherapy has a good safety profile in patients with locally advanced soft tissue sarcoma (STS), who have an important risk of relapse and few treatment options.

These results allow Nanobiotix to proceed to the pivotal phase, which is the final step leading to registration (CE mark).

The study showed that promising signs of antitumor activity for different sarcoma subtypes were observed. Interestingly, tumor shrinkage and pathological response were observed in well-known refractory tumors. All patients underwent a wide surgical resection. This optimal surgery impacts the local recurrence rate, improving patient prognosis since local disease control prolongs progression free survival and overall survival in high grade sarcomas.

Elsa Borghi, CMO of Nanobiotix said: “These results are really encouraging, the feasibility of injecting different sarcoma subtypes with varying volumes of NBTXR3 nanoparticles was tested in this phase I study and a very good tolerance was observed. We are pleased to announce that each patient has been successfully operated on. This has reinforced the fact that radiotherapy with NBTXR3 has the potential to be an effective pre-operative treatment and offer meaningful clinical benefit to patients with advanced Soft Tissue Sarcoma (STS). Now, further development of NBTXR3 is warranted and a pivotal trial is planned to start in Q4 2014.”

The study enrolled 20 patients who received a single intratumoral injection of NBTXR3, at escalating volumes, followed by standard radiotherapy (50Gy RTx), as indicated in this clinical setting.

Primary endpoints included feasibility of the intratumoral implantation and safety. Secondary endpoints focused on the efficacy such as pathological response and RECIST (Response Evaluation Criteria In Solid Tumors) response, including tumor volume evaluation. Moreover, IntraTumoral permanence of NBTXR3 and operability were assessed.

Key findings:

Feasibility of the NBTXR3 injection within the tumor mass across different tumor types and volumes (from 55.06ml to 3682.56ml) was demonstrated.
No leakage of NBTXR3 to the surrounding healthy tissues was confirmed.
• Persistence of NBTXR3 during all sessions of radiotherapy: optimal bioavailability over time.
• Appropriate dispersion of the product within the tumor: diffusion in 3 dimensions.
Very good tolerance and local safety of the product at volume 2.5%, 5%, 10% and 20% was observed.
Promising signs of antitumor activity were observed in different sarcoma subtypes, such as undifferentiated sarcoma, rhabdomyosarcoma, and synovial sarcoma.
The recommended volume for the pivotal study is 10%.

Laurent Levy, CEO of Nanobiotix commented: “The completion of this Phase I study is a very important milestone for Nanobiotix. The next step for us is to initiate a pivotal study for NBTXR3 in patients with advanced soft tissue sarcomas. We expect to start enrolling patients by the end of 2014. This successful feasibility of our NBTXR3 approach in cancer patients also encourages us to expand the use of NBTXR3 in other indications like head and neck cancer, liver cancer, glioblastoma, rectal cancer and prostate cancer, and to think about developments of our other products, NBTX-IV and NBTX-TOPO.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.
Friday, July 05, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos